ABSTRACT
This review highlights noteworthy literature pertinent to anesthesiologists and critical care physicians caring for patients undergoing abdominal organ transplantation. In 2021, we identified noteworthy papers from over 1,200 peer-reviewed publications on pancreatic transplantation, over 1,400 on intestinal transplantation, and over 9,000 on kidney transplantation. The liver transplantation section focuses on clinical trials and systematic reviews and meta-analyses published in 2021 and features 20 selected papers. COVID-19 and abdominal organ transplantation are featured in an independent section.
Subject(s)
COVID-19 , Kidney Transplantation , Organ Transplantation , Pancreas Transplantation , Anesthesiologists , HumansABSTRACT
INTRODUCTION: During the COVID-19 pandemic, the national transplant activity has been reduced due to the overload of the health system and concern for patient safety in this situation. The aim of our work is to expose the activity of kidney transplantation in Cantabria during the state of alarm, as well as to assess the safety of the transplantation program. MATERIAL AND METHODS: Retrospective study of kidney transplants performed in our Center from the beginning of the state of alarm until the beginning of the lockdown easing in Cantabria. Descriptive analysis of the demographic data of recipients and their donors, intraoperative data and postoperative outcomes. Comparative analysis with the data of the same period in 2017-2019, by means of the χ2 for categorical variables, Student's T and Mann-Whitney U tests in case of quantitative variables of normal and non-normal distribution, respectively. RESULTS: Fifteen kidney transplants were performed in the period described. Delayed renal function (DRF) was seen in 7.5% of patients, and 26.6% showed data of acute rejection; no patient presented COVID-19 disease. Comparative analysis showed a remarkable increase in the number of transplants in comparison with previous periods (15 vs 5.6), at the expense of donors from outside Cantabria (93.3%). We found no statistically significant differences in terms of cold ischemia time (p=0.77), DRF (p=0.73), need for dialysis (p=0.54), or appearance of post-surgical complications (p=0.61). CONCLUSIONS: The evolution of the pandemic in our region, and the adoption of strict protective measures has allowed the early and safe resumption of the renal transplantation program, increasing the number of transplants performed compared to previous years and maintaining comparable early post-operative results.
Subject(s)
COVID-19 , Kidney Transplantation , Pandemics , Adult , Antilymphocyte Serum/therapeutic use , COVID-19/epidemiology , COVID-19/prevention & control , Cold Ischemia , Comorbidity , Diabetes Mellitus/epidemiology , Disease Susceptibility , Female , Graft Rejection/prevention & control , Graft Rejection/therapy , Humans , Hypertension/epidemiology , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Kidney Diseases/surgery , Kidney Transplantation/methods , Kidney Transplantation/statistics & numerical data , Kidney Tubular Necrosis, Acute/chemically induced , Kidney Tubular Necrosis, Acute/prevention & control , Male , Middle Aged , Obesity/epidemiology , Pancreas Transplantation/statistics & numerical data , Plasmapheresis , Renal Replacement Therapy , Reoperation/statistics & numerical data , Retrospective Studies , Risk , Spain/epidemiology , Treatment OutcomeSubject(s)
Antilymphocyte Serum/administration & dosage , COVID-19/epidemiology , Graft Rejection/drug therapy , Kidney Transplantation/adverse effects , Pancreas Transplantation/adverse effects , Transplant Recipients , Animals , Comorbidity , Female , Humans , Immunologic Factors/administration & dosage , Immunosuppressive Agents , Male , Middle Aged , Pandemics , Rabbits , SARS-CoV-2ABSTRACT
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.
Subject(s)
Coronavirus Infections/complications , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Liver Diseases/drug therapy , Pancreatic Diseases/drug therapy , Pandemics , Pneumonia, Viral/complications , COVID-19 , Humans , Liver Diseases/complications , Liver Transplantation , Pancreas Transplantation , Pancreatic Diseases/complicationsABSTRACT
Coronavirus disease 2019 (COVID-19) has become a pandemic since first being described in January 2020. Clinical manifestations in non-transplant patients range from asymptomatic infection to severe pneumonia with acute respiratory distress syndrome, multiorgan system failure, and death. Limited reports in kidney transplant recipients suggest similar characteristics in that population. We report here the first case series of COVID-19 infection occurring in pancreas transplant recipients.